- [Resource Hub](/) - [Resource](/?resource-type=poster#library) - Analytic validation of an assay to detect androgen receptor splice variant ARv7 protein expression on circulating tumor cells from prostate cancer patients # Analytic validation of an assay to detect androgen receptor splice variant ARv7 protein expression on circulating tumor cells from prostate cancer patients An immunofluorescence assay that scores ARv7 on circulating tumor cells is only interpretable once its own sensitivity, specificity and repeatability are measured; this AACR 2020 poster reports that analytic validation, cell line by cell line, against ARv7-high, ARv7-low and ARv7-negative cells spiked into blood from healthy normal donors. Presented by RareCyte and the University of Washington. Read or download to see: - Analytical performance was measured cell line by cell line against a single MFI threshold of 100, chosen to hold specificity at a minimum of 0.9. Specificity on the ARv7-negative BT-474 line was 0.976; on the ARv7-high 22Rv1 line sensitivity reached 0.832, while on the ARv7-low LNCaP line sensitivity fell to 0.245. These are analytical figures measured on cell lines spiked into blood from healthy normal donors, not clinical performance in patients. - Repeatability was measured across three separate stainer runs of 7 slide replicates each. On the ARv7-high 22Rv1 line the mean ARv7-positive rate across runs was 83.4% with an inter-stainer CV of 3.0%, and mean ARv7 MFI was 460 with an inter-stainer CV of 10.8%; the ARv7-negative BT-474 line averaged 3.5% positive across the same three runs. - In a small clinical comparison, the ARv7 assay found at least as many CTCs as the base CTC detection assay used as the gold standard. Across three prostate cancer patients the gold standard counted 1, 0 and 3 CTCs against the ARv7 assay’s 1, 0 and 4, totalling 4 and 5; the authors state that a larger clinical study will be required to determine the clinical cutoff for ARv7. [Download poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) Your browser doesn’t support embedded PDFs. [Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/558dd9bd9ab2fa4c95bbc225309f5026bd3b7094.pdf) to view it. [Back to all resources](/#library) ## Related resources [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025 ### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) CyteFinder 2024 ### New Discoveries in HER2 Detection: A Novel Method of Multimodal Detection of HER2 from a Single Tube of Blood [Watch Webinar](https://www.youtube.com/watch?v=vJ3YH4z1YKI) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) CyteFinder 2024 ### Development and analytic validation of an ARv7 / PSMA dual biomarker circulating tumor cell assay [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/360436f6c2d14d82f253816115d89e2ace4233e2.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) CyteFinder 2024 ### Development and validation of an assay for the characterization of SSTR2 expression on CTCs from liquid biopsies [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f24e3e19abdbc04fe6d294d046d9639ecd410e6e.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) CyteFinder The Journal of Liquid Biopsy 2023 ### Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma [View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11863877/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) CyteFinder 2023 ### Novel method for the detection and evaluation of disease biomarkers on white blood cells from liquid biopsies [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/b4fe65d132e5579cb5e0a30c9bee5d7ff7f632ab.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) CyteFinder 2020 ### Validation of a dual-marker ARv7/SYP assay for CTC characterization [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/51dd5a4aee911d671443d768abcfc0b4f83899e8.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf) CyteFinder 2020 ### Investigation of custom biomarkers on circulating tumor cells from clinical samples using RarePlex Developer Kits [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/600f37993438d761629a40034f7702ebe3e46ee3.pdf) [Video](https://www.youtube.com/watch?v=A0dhlNEaohs) CyteFinder 2020 ### RarePlex Assays: Design and Analytical Validation [Watch Video](https://www.youtube.com/watch?v=A0dhlNEaohs) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) CyteFinder 2020 ### Validation of an assay to detect programmed death-ligand 1 (PD-L1) expression on circulating tumor cells [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/d6eac85be7627ae4445c6583acad89fea879177d.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf) CyteFinder 2019 ### Custom biomarker investigation of circulating tumor cells using RarePlex® Developer Kits [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/5962be5f1b2b288f2c069f7bd7b54890839f426a.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/886b7272733f331d2bd933c9cfa2bb97ce0e9542.pdf) CyteFinder 2018 ### Novel multi-parameter assays for investigational phenotyping of circulating tumor cells [Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/886b7272733f331d2bd933c9cfa2bb97ce0e9542.pdf)